Dongkook Pharmaceutical and Hyundai Bio Sign Contract for Manufacturing and Testing of COVID-19 Treatment 'CP-COV03' Finished Product

[Asia Economy Reporter Lee Gwan-joo] Dongkook Pharmaceutical and Hyundai Bioscience announced on the 18th that they have signed a consignment contract for the manufacturing and testing of the finished product of 'CP-COV03,' an oral treatment for COVID-19 currently under development.

Under this contract, Dongkook Pharmaceutical will undertake the entire consignment production process of Hyundai Bioscience's COVID-19 treatment ‘CP-COV03,’ including the procurement of raw materials, as well as overall testing procedures such as raw material testing and product release testing.

Hyundai Bioscience recently received approval from the Ministry of Food and Drug Safety for the Phase 2 clinical trial plan of CP-COV03. The Phase 2 clinical trial, involving randomized, double-blind, placebo-controlled testing on patients with mild to moderate COVID-19 symptoms, will evaluate safety and efficacy. Following this, they plan to apply for emergency use authorization and commence production immediately upon approval.

Based on its accumulated technology and experience, Dongkook Pharmaceutical plans to play a role as a production network capable of responding to domestic and global demand once CP-COV03 is launched, while expanding cooperation between the two companies for successful domestic and global development.

This content was produced with the assistance of AI translation services.